Affinage

STAB1

Stabilin-1 · UniProt Q9NY15

Length
2570 aa
Mass
275.5 kDa
Annotated
2026-06-10
27 papers in source corpus 19 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

STAB1 (stabilin-1/CLEVER-1/FEEL-1) is a large multidomain transmembrane scavenger and adhesion receptor that operates at the interface of endocytic clearance and immune cell trafficking (PMID:12473645, PMID:15297319). As an endocytic receptor it binds and internalizes advanced glycation end products and acetylated LDL with high affinity, a SR-A-type polyanion-sensitive activity, and also captures Gram-negative and Gram-positive bacteria (PMID:12473645, PMID:12077138). The receptor is predominantly intracellular and cycles rapidly between the plasma membrane and EEA-1+ early endosomes through a cytoplasmic dileucine (DXXLL) sorting signal, while its Link domain does not bind hyaluronan (PMID:15345716); this trafficking and protein stability are governed by sorting nexin 17 (SNX17), which binds the cytoplasmic NPxF motif and protects the receptor from degradation (PMID:20226821). On lymphatic and inflamed vascular endothelium, STAB1 supports leukocyte rolling and transmigration and directs in vivo homing of T and B lymphocytes, monocytes, and dendritic cells, including red-pulp entry into the spleen and CXCL13-dependent B cell trafficking (PMID:15297319, PMID:19830743, PMID:30926591, PMID:33746947). On macrophages STAB1 enforces an immunosuppressive, tolerogenic state: its loss or antibody blockade (bexmarilimab/FP-1305) reprograms macrophages toward a proinflammatory phenotype by impairing vacuolar-ATPase-mediated endosomal acidification, relieving suppression of NF-κB and PPARγ-driven lipid metabolism, and thereby reactivating endogenous antitumor CD8+ T cells synergistically with anti-PD-1 (PMID:30755440, PMID:34078651, PMID:40404204). A soluble shed form (sClever-1), generated by serine-protease cleavage, binds activated T cells via mannose-6-phosphate/IGF2R to impair TCR signaling and Th1 expansion (PMID:40756372). Consistent with these dual scavenging and immune roles, STAB1 knockout reduces primary and metastatic tumor growth (PMID:25320356), and in humans bi-allelic loss-of-function variants in STAB1 cause inherited hyperferritinemia without iron overload, revealing a role in ferritin metabolism (PMID:37490907).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2002 High

    Established STAB1 as a functional endocytic scavenger receptor, answering what molecular ligands it clears.

    Evidence Radioligand binding and uptake/degradation assays in CHO cells overexpressing FEEL-1, with polyanion competition and antibody blocking on endothelial cells

    PMID:12077138 PMID:12473645

    Open questions at the time
    • Binding domain on STAB1 not mapped
    • In vivo physiological clearance role not addressed
  2. 2003 Medium

    Showed STAB1 (CLEVER-1) on lymphatic endothelium mediates tumor cell adhesion, linking the receptor to cancer cell dissemination.

    Evidence In vitro adhesion assays with antibody blocking of CLEVER-1 and mannose receptor on lymphatic endothelial cells

    PMID:12907648

    Open questions at the time
    • Adhesion ligand on cancer cells not identified
    • No in vivo metastasis confirmation in this study
  3. 2004 High

    Defined STAB1 as an adhesion molecule supporting leukocyte transmigration and clarified its subcellular trafficking and sorting determinants.

    Evidence Flow chamber and transmigration assays; chimeric domain-swapping, EEA-1 colocalization, and ligand uptake in HeLa cells

    PMID:15297319 PMID:15345716

    Open questions at the time
    • Dileucine signal function shown as putative, not mutationally proven here
    • Endothelial counter-receptor on leukocytes unidentified
  4. 2009 High

    Demonstrated STAB1 controls in vivo lymphocyte and myeloid cell migration, moving the receptor from in vitro adhesion to physiological inflammatory trafficking.

    Evidence In vivo lymphocyte migration and peritonitis models with antibody blocking, adoptive transfer, and epitope mapping in mice

    PMID:19830743

    Open questions at the time
    • Adhesive epitope's molecular ligand not defined
    • Cell-intrinsic vs endothelial contribution not fully separated
  5. 2010 High

    Identified SNX17 as a direct cytoplasmic-tail partner that controls STAB1 stability, explaining how receptor levels and ligand uptake are post-translationally regulated.

    Evidence Co-immunoprecipitation, NPxF-motif mutagenesis, and SNX17 siRNA knockdown with ligand uptake readout

    PMID:20226821

    Open questions at the time
    • Degradation route protected by SNX17 not defined
    • No structural detail of the NPxF–PX interaction
  6. 2011 Medium

    Extended STAB1 function to tissue macrophages, linking scavenging activity to cytokine output and macrophage adhesion/transmigration.

    Evidence siRNA knockdown in human placental macrophages with ligand uptake, cytokine profiling, and transmigration assays

    PMID:21480214

    Open questions at the time
    • Signaling pathway connecting STAB1 to cytokine changes not defined
    • Single tissue context
  7. 2014 High

    Established STAB1 as a pro-tumoral receptor in vivo, showing genetic loss and antibody blockade reduce tumor growth via immunosuppressive leukocyte recruitment.

    Evidence Full and cell-type-specific conditional knockout mice, bone marrow chimeras, and anti-Clever-1 antibody therapy in melanoma and lymphoma models

    PMID:25320356

    Open questions at the time
    • Molecular mechanism of immunosuppression not yet defined here
    • Endothelial vs macrophage relative contributions partially resolved
  8. 2019 High

    Defined the immunosuppressive mechanism: macrophage STAB1 restrains antitumor CD8+ T cells, and its blockade synergizes with anti-PD-1.

    Evidence Conditional knockout, chimeras, cell depletion, and anti-Clever-1 ± anti-PD-1 immunotherapy across multiple mouse tumor models

    PMID:30755440

    Open questions at the time
    • Downstream molecular effector of macrophage suppression not yet identified in this study
    • Direct vs indirect effect on T cells unclear
  9. 2019 Medium

    Localized STAB1 trafficking control to splenic red-pulp vessels and connected it to chemokine-dependent B cell homing.

    Evidence Genetic ablation with ex vivo adhesion assays, homing assays, and CXCL13 expression analysis on spleen endothelium

    PMID:30926591

    Open questions at the time
    • Mechanism linking STAB1 loss to CXCL13 downregulation unknown
    • Consequences for systemic immunity not assessed
  10. 2021 Medium

    Resolved the molecular basis of macrophage tolerance: STAB1 blockade impairs V-ATPase endosomal acidification and rewires nuclear lipid signaling to enhance T cell activation.

    Evidence Antibody pull-down interactome, mass cytometry, RNA-seq, and cytokine profiling in primary human macrophages with clinical trial patient samples; lymphatic endothelial knockout DC trafficking assays

    PMID:33746947 PMID:34078651

    Open questions at the time
    • Direct vs indirect V-ATPase interaction not biochemically resolved
    • Link between acidification defect and lipid signaling switch incomplete
  11. 2023 Medium

    Connected STAB1 to a human Mendelian phenotype, revealing an unexpected role in ferritin metabolism.

    Evidence Whole-exome sequencing with homozygosity mapping plus protein expression analysis in liver, monocytes, and macrophages of affected individuals

    PMID:37490907

    Open questions at the time
    • Mechanistic link between STAB1 loss and hyperferritinemia not reconstituted
    • Whether ferritin is a direct ligand unknown
  12. 2025 High

    Identified a soluble shed form of STAB1 acting in trans on T cells, defining a secreted immunosuppressive mechanism via IGF2R.

    Evidence Serine protease inhibitor studies, recombinant sClever-1 biophysics, pulldown/MS, T cell activation and Jurkat reporter assays, EV isolation, and tumor explants

    PMID:40756372

    Open questions at the time
    • Identity of the responsible serine protease not pinned down
    • Relative in vivo contribution of soluble vs membrane STAB1 unresolved
  13. 2025 Medium

    Extended STAB1's tumor-promoting role to cell-intrinsic AML survival and to transcriptional control of M2 macrophage polarization.

    Evidence STAB1 knockdown in AML cell lines with NF-κB pathway and xenograft readouts; HNF4A/NCOA2/GR axis with ChIP, co-IP, and IL-4-driven macrophage polarization assays; bexmarilimab gastric cancer TAM reprogramming via PPARγ

    PMID:39979267 PMID:40083109 PMID:40404204

    Open questions at the time
    • Whether STAB1 signals directly into IKK/NF-κB or acts indirectly is unresolved
    • Mechanism connecting STAB1 to PPARγ lipid metabolism incomplete

Open questions

Synthesis pass · forward-looking unresolved questions
  • The biochemical mechanism linking STAB1 to ferritin handling and the direct signaling output of the receptor's cytoplasmic tail remain undefined.
  • No reconstitution of STAB1-dependent ferritin uptake or efflux
  • Direct intracellular signaling effectors of STAB1 not identified
  • Structural basis of ligand and partner binding unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0038024 cargo receptor activity 3 GO:0098631 cell adhesion mediator activity 3 GO:0001618 virus receptor activity 1
Localization
GO:0005768 endosome 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-168256 Immune System 4 R-HSA-1500931 Cell-Cell communication 3 R-HSA-5653656 Vesicle-mediated transport 2
Partners
IGF2RSNX17

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 FEEL-1 (STAB1) functions as an endocytic receptor for advanced glycation end products (AGEs): CHO cells overexpressing FEEL-1 bound 125I-AGE-BSA with high affinity (Kd ~2.55 µg/ml) at 4°C, and at 37°C took up and degraded the ligand; binding was inhibited by polyanionic SR-A inhibitors (fucoidan, polyinosinic acid, dextran sulfate) but not by native or oxidized LDL. Radioligand binding assay and uptake/degradation assay in CHO cells overexpressing FEEL-1; competitive inhibition with polyanionic ligands The Journal of biological chemistry High 12473645
2002 FEEL-1 (STAB1) is the major receptor for acetylated LDL (Ac-LDL) on human umbilical vein endothelial cells, as demonstrated by monoclonal antibody blocking; FEEL-1 and FEEL-2 expressed in CHO cells both bind DiI-Ac-LDL and Gram-negative and Gram-positive bacteria; inhibition of FEEL-1 with monoclonal antibody markedly reduced cell-cell interaction in the Matrigel tube formation assay, indicating a role in angiogenesis. Expression cloning; monoclonal antibody blocking of DiI-Ac-LDL uptake; transient overexpression in CHO cells; in vitro Matrigel tube formation assay The Journal of biological chemistry Medium 12077138
2003 CLEVER-1 (STAB1) on lymphatic endothelium mediates adhesion of head-and-neck cancer cell lines to lymphatic endothelium; adhesion of all tested cancer cell lines was dependent on both CLEVER-1 and mannose receptor, as shown by antibody blocking experiments. In vitro adhesion assays with antibody blocking of CLEVER-1 and mannose receptor on lymphatic endothelial cells Cancer research Medium 12907648
2004 CLEVER-1 (STAB1) supports rolling and transmigration of peripheral blood mononuclear cells (PBMCs) across vascular endothelium under physiological laminar shear stress, and also mediates transmigration of leukocytes through lymphatic endothelium under static conditions; CLEVER-1 is constitutively expressed on lymphatic vessels in skin and induced on vascular endothelium upon inflammation. Flow chamber assay under shear stress; transmigration assay through cultured lymphatic endothelium; immunofluorescence of tissue sections Blood High 15297319
2004 Stabilin-1 (STAB1) is predominantly intracellular and cycles rapidly between the plasma membrane and EEA-1+ early endosomes; intracellular targeting is influenced by the transmembrane domain/cytoplasmic tail, which contains a putative dileucine (DXXLL) Golgi-to-endosomal sorting signal; the stabilin-1 Link domain does not bind hyaluronan or other glycosaminoglycans. Fluorescent antibody and Fl-Ac-LDL uptake assays; subcellular fractionation/immunofluorescence colocalization with EEA-1; stabilin-1/CD44 chimera expression in HeLa cells; hyaluronan binding assay The Journal of biological chemistry High 15345716
2009 Clever-1/Stabilin-1 mediates in vivo migration of T and B lymphocytes to draining lymph nodes via lymphatics; an adhesive epitope on Clever-1/Stabilin-1 responsible for the interaction between lymphocytes and lymphatic endothelium was identified; antibody blocking of Clever-1/Stabilin-1 inhibited peritonitis in mice by reducing granulocyte entrance by ~50% and nearly abolishing monocyte and lymphocyte migration into the inflamed peritoneum. In vivo lymphocyte migration models; antibody blocking in peritonitis mouse model; adoptive transfer experiments; epitope mapping European journal of immunology High 19830743
2010 Sorting nexin 17 (SNX17), a phox-homology domain protein, directly interacts with the cytoplasmic tail of FEEL-1/stabilin-1 via the NPxF motif; SNX17 regulates FEEL-1/stabilin-1 trafficking and siRNA knockdown of SNX17 decreases total cellular FEEL-1/stabilin-1 expression and FEEL-1-mediated ligand uptake by enhancing protein degradation. Co-immunoprecipitation; cytoplasmic domain truncation and point-mutation constructs; siRNA knockdown; ligand uptake assay Biochimica et biophysica acta High 20226821
2011 Stabilin-1/CLEVER-1 on human placental macrophages mediates scavenging of Ac-LDL and uptake of fluorescently labeled OVA; siRNA-mediated suppression of stabilin-1/CLEVER-1 alters the cytokine profile produced by placental macrophages; stabilin-1/CLEVER-1 on placental macrophages mediates their adhesion to placental vessels and supports transmigration through vascular endothelium. siRNA knockdown; fluorescent ligand uptake assay; cytokine profiling; transmigration assay; flow cytometry European journal of immunology Medium 21480214
2014 Clever-1/Stabilin-1 deficiency (full knockout and macrophage- or endothelium-specific conditional knockouts) reduces primary and metastatic tumor growth in mice; Clever-1 mediates binding of immunosuppressive leukocytes to intratumoral blood vessels and facilitates tumor cell traffic via lymphatics; anti-Clever-1 antibody treatment inhibits tumor progression in wild-type mice. Full and conditional knockout mice (macrophage-specific, endothelium-specific); bone marrow chimeras; cell depletion experiments; anti-Clever-1 antibody therapy in B16 melanoma and EL-4 lymphoma models; flow cytometry of tumor-infiltrating leukocytes Clinical cancer research High 25320356
2018 Clever-1-deficient macrophages show increased TNF-α synthesis; in co-culture, Clever-1-deficient monocytes/macrophages support higher IgM production by B cells in a TNF-α-dependent manner; macrophage-specific Clever-1 ablation results in elevated IgG levels and enhanced humoral immune responses in vivo. Stab1 knockout mice; macrophage-specific conditional knockout; ELISA for antibody levels and cytokines; B cell–macrophage co-culture; TNF-α depletion experiments Frontiers in immunology Medium 30349531
2019 Genetic deficiency of macrophage Clever-1 impairs solid tumor growth by converting macrophages from immunosuppressive to immunostimulatory, thereby activating endogenous antitumor CD8+ T cells; therapeutic blockade of Clever-1 has comparable effects and synergizes with anti-PD-1 in aggressive tumors. Conditional Clever-1 knockout; bone marrow chimeras; cell depletion experiments; anti-Clever-1 immunotherapy alone and combined with anti-PD-1 in multiple mouse cancer models; flow cytometry Clinical cancer research High 30755440
2019 Clever-1 controls CD8+ T cell and B220+ B cell homing to the spleen specifically via vessels in the red pulp; absence of Clever-1 leads to downregulation of the B cell attractant chemokine CXCL13 on spleen endothelium, contributing to reduced B cell trafficking into the spleen. Ex vivo adhesion assays in mice and humans; genetic ablation of Clever-1 in mice; CXCL13 expression analysis on spleen endothelium; adoptive transfer / homing assays Science immunology Medium 30926591
2021 Anti-Clever-1 antibody FP-1305 (bexmarilimab) impairs multiprotein vacuolar ATPase-mediated endosomal acidification in primary human macrophages (identified by pull-down interactome assays) and improves the ability of macrophages to activate CD8+ T cells; in patients, FP-1305 suppresses nuclear lipid signaling and induces a proinflammatory phenotypic switch in blood monocytes. Antibody pull-down assays in primary human macrophages; mass cytometry; RNA sequencing; cytokine profiling; clinical trial patient samples (n=30) Clinical cancer research Medium 34078651
2021 Clever-1 on lymphatic endothelial cells (LECs) promotes immunosuppression towards migrating dendritic cells; Clever-1 knockout impairs DC entrance into afferent lymphatics and reduces DC trafficking to draining lymph nodes; LECs in Clever-1 KO lymph nodes display a less tolerogenic phenotype with increased MHC II on DCs, enabling stronger OVA-specific T cell proliferative responses despite fewer DCs reaching the node. Clever-1 knockout mice; adoptive DC transfer experiments; flow cytometry; MHC II expression analysis; antigen-specific T cell proliferation assay Frontiers in immunology Medium 33746947
2023 Bi-allelic loss-of-function variants in STAB1 are associated with inherited hyperferritinemia without iron overload in humans; immunohistochemistry and flow cytometry confirmed absent or markedly reduced stabilin-1 protein in liver samples, monocytes, and monocyte-derived macrophages of affected individuals, implicating stabilin-1 in ferritin metabolism. Whole-exome sequencing with homozygosity mapping; immunohistochemistry of liver biopsies; flow cytometry of monocytes and macrophages American journal of human genetics Medium 37490907
2025 Secreted Clever-1 (sClever-1) is released from macrophages by IFNγ/LPS-induced serine protease-dependent cleavage; recombinant sClever-1 binds selectively to activated T cells via mannose-6-phosphate-mediated interaction with IGF2R, impairing TCR signaling and Th1 expansion; sClever-1 is also associated with macrophage-derived extracellular vesicles and contributes to T cell tolerance and reduced anti-PD-1 efficacy. TRFIA-based ELISA of plasma samples; recombinant protein production and biophysical characterization; flow cytometry; Western blotting; T cell activation assays; Jurkat reporter systems; extracellular vesicle isolation; pulldown assays with mass spectrometry; serine protease inhibitor studies; patient-derived tumor explants Theranostics High 40756372
2025 STAB1 knockdown in AML cell lines (HEL and NB4) suppresses proliferation and promotes apoptosis through downregulation of the IKK/NF-κB pathway; conditioned medium from STAB1-knockdown AML cells reduces M2 polarization of co-cultured macrophages; in vivo STAB1 silencing prolongs survival and reduces AML aggressiveness in xenograft models. siRNA/shRNA knockdown in AML cell lines; cell proliferation and apoptosis assays; NF-κB pathway activity assays; macrophage co-culture with conditioned medium; xenograft mouse models Cancer science Medium 40083109
2025 HNF4A transcriptionally regulates NCOA2 by binding its promoter; NCOA2 interacts with glucocorticoid receptor (GR); STAB1 is identified as a downstream target gene of the HNF4A/NCOA2/GR transcriptional axis, with STAB1 expression required for IL-4-induced M2 macrophage polarization in the context of sepsis-associated lung injury. Adenovirus-mediated HNF4A overexpression in mouse sepsis model (cecal ligation and puncture); ChIP/promoter binding assay for HNF4A-NCOA2; co-immunoprecipitation for NCOA2-GR; transcriptome sequencing; in vitro IL-4-stimulated bone marrow-derived macrophage polarization with STAB1 inhibition Cell death & disease Medium 39979267
2025 CLEVER-1 blockade (bexmarilimab) reprograms tumor-associated macrophages (TAMs) toward a pro-inflammatory phenotype in gastric cancer by suppressing PPARγ-driven lipid metabolism and enhancing antigen presentation and inflammatory cytokine secretion; CLEVER-1 blockade synergizes with anti-PD-1 in ex vivo gastric cancer models. Flow cytometry; transcriptomic analysis of reprogrammed TAMs; ex vivo gastric cancer tumor models with bexmarilimab ± anti-PD-1; PPARγ pathway analysis Journal for immunotherapy of cancer Medium 40404204

Source papers

Stage 0 corpus · 27 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. The Journal of biological chemistry 151 12473645
2002 FEEL-1, a novel scavenger receptor with in vitro bacteria-binding and angiogenesis-modulating activities. The Journal of biological chemistry 145 12077138
2003 Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer research 112 12907648
2004 CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium. Blood 105 15297319
2019 Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 93 30755440
2014 Clever-1/stabilin-1 controls cancer growth and metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research 84 25320356
2009 Clever-1/Stabilin-1 regulates lymphocyte migration within lymphatics and leukocyte entrance to sites of inflammation. European journal of immunology 80 19830743
2004 Rapid plasma membrane-endosomal trafficking of the lymph node sinus and high endothelial venule scavenger receptor/homing receptor stabilin-1 (FEEL-1/CLEVER-1). The Journal of biological chemistry 74 15345716
2011 Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages. European journal of immunology 50 21480214
2021 Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 47 34078651
2021 Lymphatic Endothelial Cell Activation and Dendritic Cell Transmigration Is Modified by Genetic Deletion of Clever-1. Frontiers in immunology 24 33746947
2010 Adaptor protein sorting nexin 17 interacts with the scavenger receptor FEEL-1/stabilin-1 and modulates its expression on the cell surface. Biochimica et biophysica acta 24 20226821
2019 Clever-1 contributes to lymphocyte entry into the spleen via the red pulp. Science immunology 16 30926591
2022 Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers. Molecular cancer therapeutics 14 35500016
2018 Enhanced Antibody Production in Clever-1/Stabilin-1-Deficient Mice. Frontiers in immunology 14 30349531
2025 Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer. Journal for immunotherapy of cancer 12 40404204
2011 Lymphatic expression of CLEVER-1 in breast cancer and its relationship with lymph node metastasis. Analytical cellular pathology (Amsterdam) 12 21483103
2025 HNF4A mitigates sepsis-associated lung injury by upregulating NCOR2/GR/STAB1 axis and promoting macrophage polarization towards M2 phenotype. Cell death & disease 11 39979267
2025 STAB1 Promotes Acute Myeloid Leukemia Progression by Activating the IKK/NF-κB Pathway and Increasing M2 Macrophage Polarization. Cancer science 8 40083109
2025 Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy. Theranostics 8 40756372
2022 Clever-1 positive macrophages in breast cancer. Breast cancer research and treatment 8 35917053
2025 CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies. Scientific reports 5 40369178
2023 A form of inherited hyperferritinemia associated with bi-allelic pathogenic variants of STAB1. American journal of human genetics 3 37490907
2025 CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer. Journal for immunotherapy of cancer 1 41339106
2026 Integrated single-cell and bulk transcriptomics reveals STAB1 as a novel therapeutic target for ovarian cancer. Translational oncology 0 41865597
2025 Generation of two human induced pluripotent stem cell lines from peripheral blood mononuclear cells featuring normal or mutated STAB1 gene. Stem cell research 0 40482634
2025 Multi-modal integration of histopathology and transcriptomics reveals STAB1+ macrophage-associated efferocytosis as a suppressive immune mechanism in colon adenocarcinoma. Journal of translational medicine 0 41361444

Missed literature

Know a paper Affinage missed for STAB1? Flag it for the maintainers and the community.

No submissions yet.